Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate

Next Previous
Trial Profile

A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diroximel-fumarate (Primary) ; Dimethyl fumarate
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE-2; EVOLVE-MS-2
  • Sponsors Alkermes plc; Biogen

Most Recent Events

  • 16 Nov 2021 According to a Biogen media release, the European Commission (EC) has granted marketing authorization for VUMERITY (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS).
  • 15 Oct 2021 Results comparing the impact of dose titration on gastrointestinal tolerability presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
  • 15 Oct 2021 Results of post hoc analysis of incidence, severity, and duration of flushing and flushing-related treatment-emergent adverse events with Diroximel fumarate versus dimethyl fumarate over 5 weeks, presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top